Download PDF
CC BY-NC-ND 4.0 · Annals of Otology and Neurotology 2020; 3(01): 16-22
DOI: 10.1055/s-0040-1715289
Original Article

Assessment of Hearing Loss in Patients Receiving Chemoradiotherapy in Adjuvant Setting for Head and Neck Malignancy

Vani Krishana Gupta
1   Department of ENT, Father Muller Medical College, Mangalore, Karnataka, India
,
Mahesh Bhat
1   Department of ENT, Father Muller Medical College, Mangalore, Karnataka, India
,
Vinay Vaidyanathan Rao
1   Department of ENT, Father Muller Medical College, Mangalore, Karnataka, India
,
Vishak Surendra
1   Department of ENT, Father Muller Medical College, Mangalore, Karnataka, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Introduction The aim of the study is to assess the hearing loss in patients who receive chemoradiation (chemoradiotherapy or CTRT) for head and neck malignancies.

Materials and Methods Prospective study was conducted in the Department of ENT of a tertiary care center from September 2013 to August 2014. Forty patients suffering from head and neck malignancies (histologically proven) were included in the study. Patients with pre-existing hearing loss were excluded. All patients received radiotherapy dose of 66 to 70 Gy given as 2 Gy/d, 5 d/wk and chemotherapy dose of cisplatin 35 mg/m2 once a week for 6 weeks. Hearing was assessed by pure tone audiometry (PTA) and impedance audiometry conducted at regular intervals. Mcnemars chi-square test was used to compare the impedance and paired t-test and Pearson’s correlation were used to compare PTA at various stages.

Results Predominantly male patients (28) falling in the age group of 40 to 60 years, suffered from various head and neck cancer, most common being oropharynx (14). Twenty patients developed sensorineural hearing loss (SNHL)—11(55%) had mild, seven (35%) had moderate, and two (10%) had severe grade of SNHL. Majority of these patients, 12 (60%) started developing SNHL mid-therapy, five (25%) at the completion of therapy and three (15%) 3 months post-therapy. Hearing loss was found to be more with two-dimensional radiotherapy (2DRT) and three-dimensional radiotherapy (3DRT) than with intensity-modulated radiotherapy (IMRT) as assessed by serial PTA. The average dose of radiation to right and left ears, respectively were 27.10 and 24.66 Gy. The incidence of otitis media with effusion increased during the treatment accounting for the conductive hearing loss irrespective of the modality of radiation used.

Conclusion CTRT causes significant hearing loss in patients suffering from head and neck malignancies leading to further increase in the morbidity. Screening audiological assessment would be helpful to know the pretherapy status of the ear. Using newer modalities like IMRT can reduce hearing loss. Regular audiological screening can catch it at its onset and help in early use of hearing aids.

Keywords

chemoradiation - head and neck malignancies - two-dimensional radiotherapy - three-dimensional radiotherapy - intensity-modulated radiotherapy - sensorineural hearing loss - conductive hearing loss


Publication History

Article published online:
12 August 2020

© .

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kulkarni MR. Head and neck cancer burden in India. Int J Head Neck Surg 2013; 4 (01) 29-35
    Google Scholar
  • 2 Olusanya BO, Davis AC, Hoffman HJ. Hearing loss grades and the International classification of functioning, disability and health. Bull World Health Organ 2019; 97 (10) 725-728
    CrossrefPubMedGoogle Scholar
  • 3 Linskey ME, Johnstone PAS. Radiation tolerance of normal temporal bone structures: implications for gamma knife stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2003; 57 (01) 196-200
    CrossrefPubMedGoogle Scholar
  • 4 Low WK, Toh ST, Wee J, Fook-Chong SMC, Wang DY. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 2006; 24 (12) 1904-1909
    CrossrefPubMedGoogle Scholar
  • 5 Talmi YP, Finkelstein Y, Zohar Y. Postirradiation hearing loss. Audiology 1989; 28 (03) 121-126
    CrossrefPubMedGoogle Scholar
  • 6 Ho WK, Wei WI, Kwong DL. et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck 1999; 21 (06) 547-553
    CrossrefPubMedGoogle Scholar
  • 7 Kwong DLW, Wei WI, Sham JST. et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys 1996; 36 (02) 281-289
    CrossrefPubMedGoogle Scholar
  • 8 Grau C, Overgaard J. Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int J Radiat Oncol Biol Phys 1996; 36 (02) 515-517
    CrossrefPubMedGoogle Scholar
  • 9 Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM. Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 2007; 67 (02) 469-479
    CrossrefPubMedGoogle Scholar
  • 10 Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Pediatrics 2010; 125 (04) e938-e950
    CrossrefPubMedGoogle Scholar
  • 11 Grau C, Møller K, Overgaard M, Overgaard J, Elbrønd O. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1991; 21 (03) 723-728
    CrossrefPubMedGoogle Scholar
  • 12 Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, Kileny PR. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2005; 61 (05) 1393-1402
    CrossrefPubMedGoogle Scholar
  • 13 Raaijmakers E, Engelen AM. Is sensorineural hearing loss a possible side effect of nasopharyngeal and parotid irradiation? A systematic review of the literature. Radiother Oncol 2002; 65 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 14 Zuur CL, Simis YJ, Lamers EA. et al. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2009; 74 (02) 490-496
    CrossrefPubMedGoogle Scholar
  • 15 Herrmann F, Dörr W, Müller R, Herrmann T. A prospective study on radiation-induced changes in hearing function. Int J Radiat Oncol Biol Phys 2006; 65 (05) 1338-1344
    CrossrefPubMedGoogle Scholar
  • 16 Honoré HB, Bentzen SM, Møller K, Grau C. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol 2002; 65 (01) 9-16
    CrossrefPubMedGoogle Scholar
  • 17 Merchant TE, Gould CJ, Xiong X. et al. Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys 2004; 58 (04) 1194-1207
    CrossrefPubMedGoogle Scholar
  • 18 van der Veen J, Nuyts S. Can intensity-modulated-radiotherapy reduce toxicity in head and neck squamous cell carcinoma?. Cancers (Basel) 2017; 9 (10) E135
    CrossrefPubMedGoogle Scholar
  • 19 Ge X, Liao Z, Yuan J. et al. Radiotherapy-related quality of life in patients with head and neck cancers: a meta-analysis. Support Care Cancer 2020; 28 (06) 2701-2712
    CrossrefPubMedGoogle Scholar
  • 20 Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain?. Cancer Treat Rev 2011; 37 (07) 511-519
    CrossrefPubMedGoogle Scholar
  • 21 Petsuksiri J, Sermsree A, Thephamongkhol K. et al. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients. Radiat Oncol 2011; 6 (01) 19
    CrossrefPubMedGoogle Scholar
  • 22 Theunissen EA, Zuur CL, Yurda ML. et al. Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study. J Otolaryngol Head Neck Surg 2014; 43 (01) 30
    CrossrefPubMedGoogle Scholar
  • 23 Peng G, Wang T, Yang KY. et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012; 104 (03) 286-293
    CrossrefPubMedGoogle Scholar
  • 24 Zhu B, Kou C, Bai W. et al. Accelerated hyperfractionated radiotherapy versus conventional fractionation radiotherapy for head and neck cancer: a meta-analysis of randomized controlled trials. J Oncol 2019; 2019: 7634746
    PubMedGoogle Scholar
  • 25 Liu Y, Kou C, Bai W. et al. Altered fractionation radiotherapy with or without chemotherapy in the treatment of head and neck cancer: a network meta-analysis. OncoTargets Ther 2018; 11: 5465-5483
    CrossrefPubMedGoogle Scholar
  • 26 Foote RL, Ang KK. Head and neck tumors, overview. In: Gunderson LL, Tepper JE. eds Clinical Radiation Oncology. 4th ed. Philadelphia, PA: Elsevier; 2016: 561-569
    CrossrefGoogle Scholar
  • 27 Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71 (01) 83-91
    CrossrefPubMedGoogle Scholar
  • 28 El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14 (03) 838-847
    CrossrefPubMedGoogle Scholar
  • 29 Chan SH, Ng WT, Kam KL. et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys 2009; 73 (05) 1335-1342
    CrossrefPubMedGoogle Scholar
  • 30 Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2009; 73 (03) 779-788
    CrossrefPubMedGoogle Scholar
  • 31 Mujica-Mota MA, Lehnert S, Devic S, Gasbarrino K, Daniel SJ. Mechanisms of radiation-induced sensorineural hearing loss and radioprotection. Hear Res 2014; 312: 60-68
    CrossrefPubMedGoogle Scholar
  • 32 Brizel DM, Wasserman TH, Henke M. et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18 (19) 3339-3345
    CrossrefPubMedGoogle Scholar
  • 33 Hall EJ, Cox JD. Physical and biologic basis of radiation therapy. In: Cox JD, Ang KK. eds Radiation Oncology: Rationale, Technique, Results. 9th ed. Philadelphia, PA: Mosby Elsevier; 2010: 3-49
    Google Scholar
  • 34 Fouladi M, Chintagumpala M, Ashley D. et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008; 26 (22) 3749-3755
    CrossrefPubMedGoogle Scholar
  • 35 Paulino AC, Lobo M, Teh BS. et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys 2010; 78 (05) 1445-1450
    CrossrefPubMedGoogle Scholar
  • 36 Low W-K, Sun L, Tan MGK, Chua AWC, Wang D-Y. L-N-Acetylcysteine protects against radiation-induced apoptosis in a cochlear cell line. Acta Otolaryngol 2008; 128 (04) 440-445
    CrossrefPubMedGoogle Scholar
  • 37 Pyun JH, Kang SU, Hwang HS. et al. Epicatechin inhibits radiation-induced auditory cell death by suppression of reactive oxygen species generation. Neuroscience 2011; 199: 410-420
    CrossrefPubMedGoogle Scholar
  • 38 Lau SK, Wei WI, Sham J, Hui Y, Choy D. Effect of irradiation on middle ear effusion due to nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 1992; 17 (03) 246-250
    CrossrefPubMedGoogle Scholar
  • 39 Kew J, King AD, Leung SF. et al. Middle ear effusions after radiotherapy: correlation with pre-radiotherapy nasopharyngeal tumor patterns. Am J Otol 2000; 21 (06) 782-785
    Google Scholar
  • 40 Low WK, Fong KW. Long-term hearing status after radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx 1998; 25 (01) 21-24
    CrossrefPubMedGoogle Scholar
  • 41 Emami B, Lyman J, Brown A. et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21 (01) 109-122
    CrossrefPubMedGoogle Scholar
  • 42 Wang SZ, Wang WF, Zhang HY, Guo M, Hoffman MR, Jiang JJ. Analysis of anatomical factors controlling the morbidity of radiation-induced otitis media with effusion. Radiother Oncol 2007; 85 (03) 463-468
    CrossrefPubMedGoogle Scholar
  • 43 Bhandare N, Moisseenko V, Song WY, Morris CG, Antonelli P, Mendenhall WM. Evaluating the association between pre- and postradiation therapy otitis media with effusion and the incidence of sensory-neural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol 2012; 84 (03) S515-S516
    CrossrefGoogle Scholar
  • 44 Kujawski OB, Poe DS. Laser eustachian tuboplasty. Otol Neurotol 2004; 25 (01) 1
    CrossrefPubMedGoogle Scholar
  • 45 Hsin CH, Chen TH, Liang KL, Tseng HC, Liu WS. Postirradiation otitis media with effusion in nasopharyngeal carcinoma patients treated by intensity-modulated radiotherapy. Laryngoscope 2013; 123 (09) 2148-2153
    CrossrefPubMedGoogle Scholar
  • 46 Hsin C-H, Chen T-H, Young Y-H, Liu W-S. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients. Otolaryngol Head Neck Surg 2010; 143 (05) 662-668
    CrossrefPubMedGoogle Scholar
  • 47 Skinner DW, van Hasselt CA. A study of the complications of grommet insertion for secretory otitis media in the presence of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 1991; 16 (05) 480-482
    CrossrefPubMedGoogle Scholar
  • 48 Chen CY, Young YH, Hsu WC, Hsu MM. Failure of grommet insertion in post-irradiation otitis media with effusion. Ann Otol Rhinol Laryngol 2001; 110 (08) 746-748
    CrossrefPubMedGoogle Scholar